Cantonal opioid agonist treatment authorisation systems - a mixed-method qualitative investigation.

IF 2.1 4区 医学 Q2 MEDICINE, GENERAL & INTERNAL Swiss medical weekly Pub Date : 2024-06-03 DOI:10.57187/s.3629
Caroline Schmitt-Koopmann, Carole-Anne Baud, Stéphanie Beuriot, Valérie Junod, Barbara Broers, Olivier Simon
{"title":"Cantonal opioid agonist treatment authorisation systems - a mixed-method qualitative investigation.","authors":"Caroline Schmitt-Koopmann, Carole-Anne Baud, Stéphanie Beuriot, Valérie Junod, Barbara Broers, Olivier Simon","doi":"10.57187/s.3629","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and aim: </strong>In Switzerland, a cantonal authorisation is required to introduce opioid agonist treatments (OAT). We investigated and compared the terms of these cantonal OAT authorisations throughout Switzerland. The primary objective was to determine how the overseeing cantonal officials implemented and perceived the legal requirements.</p><p><strong>Method: </strong>We started with a cross-sectional analysis of legal texts and cantonal OAT guidelines. Based on the document analysis, we conducted 26 semi-structured interviews with the cantonal officials who grant OAT authorisations.</p><p><strong>Findings: </strong>In most cantons (21 of 25), the OAT authorisation is specific to the person treated and must be renewed every year. Today, 21 cantons either have implemented or are implementing the same web-based software to process and manage OAT authorisation requests. Cantons have implemented diverging requirements regarding, amongst others, the involvement of third parties in OAT and the training required of prescribing physicians. Lastly, the OAT process does not seem to be a high priority for the overseeing officials.</p><p><strong>Conclusions: </strong>From a legal standpoint, OAT authorisations should be straightforward, yet we found significant divergences among cantonal systems. We could not find scientific evidence that supports a given framework. We recommend harmonizing the 26 cantonal systems while reviewing the need for OAT authorisation.</p>","PeriodicalId":22111,"journal":{"name":"Swiss medical weekly","volume":"154 ","pages":"3629"},"PeriodicalIF":2.1000,"publicationDate":"2024-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Swiss medical weekly","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.57187/s.3629","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

Abstract

Background and aim: In Switzerland, a cantonal authorisation is required to introduce opioid agonist treatments (OAT). We investigated and compared the terms of these cantonal OAT authorisations throughout Switzerland. The primary objective was to determine how the overseeing cantonal officials implemented and perceived the legal requirements.

Method: We started with a cross-sectional analysis of legal texts and cantonal OAT guidelines. Based on the document analysis, we conducted 26 semi-structured interviews with the cantonal officials who grant OAT authorisations.

Findings: In most cantons (21 of 25), the OAT authorisation is specific to the person treated and must be renewed every year. Today, 21 cantons either have implemented or are implementing the same web-based software to process and manage OAT authorisation requests. Cantons have implemented diverging requirements regarding, amongst others, the involvement of third parties in OAT and the training required of prescribing physicians. Lastly, the OAT process does not seem to be a high priority for the overseeing officials.

Conclusions: From a legal standpoint, OAT authorisations should be straightforward, yet we found significant divergences among cantonal systems. We could not find scientific evidence that supports a given framework. We recommend harmonizing the 26 cantonal systems while reviewing the need for OAT authorisation.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
各州阿片类激动剂治疗授权制度--一项混合方法定性调查。
背景和目的:在瑞士,采用阿片类受体激动剂治疗(OAT)需要获得州级授权。我们调查并比较了瑞士各地州级阿片类受体激动剂授权的条款。主要目的是确定负责监督的州官员是如何执行和理解法律规定的:我们首先对法律条文和各州 OAT 指南进行了横向分析。在文件分析的基础上,我们对各州负责批准 OAT 的官员进行了 26 次半结构化访谈:在大多数州(25 个州中的 21 个),OAT 授权是针对接受治疗者的,并且必须每年更新。目前,有 21 个州已经或正在使用相同的网络软件来处理和管理 OAT 授权申请。除其他外,各州对第三方参与 OAT 和处方医生培训的要求也不尽相同。最后,OAT 程序似乎并不是监督官员的首要任务:从法律角度看,OAT 授权应该是简单明了的,但我们发现各州的制度之间存在很大差异。我们无法找到支持特定框架的科学证据。我们建议统一 26 个州的制度,同时审查 OAT 授权的必要性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Swiss medical weekly
Swiss medical weekly 医学-医学:内科
CiteScore
5.00
自引率
0.00%
发文量
0
审稿时长
3-8 weeks
期刊介绍: The Swiss Medical Weekly accepts for consideration original and review articles from all fields of medicine. The quality of SMW publications is guaranteed by a consistent policy of rigorous single-blind peer review. All editorial decisions are made by research-active academics.
期刊最新文献
Supplementum 284: Abstracts of the 56th Annual meeting of the Swiss Society of Nephrology. Safety of oral immunotherapy for cashew nut and peanut allergy in children - a retrospective single-centre study. Cardiac amyloidosis. Blood pressure control and antihypertensive treatment in Swiss general practice: a cross-sectional study using routine data. Exploring the real-world management of catheter-associated urinary tract infections by Swiss general practitioners and urologists: insights from an online survey.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1